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The Genetic Basis for Cardiomyopathy: Review
from Mutation Identification
to Mechanistic Paradigms
impairs ventricular relaxation; changes that further alter
heart anatomy. Abnormal ventricular relaxation impedes
atrial emptying of blood, which can passively stretch
these thin-walled chambers and cause atrial dilation, a
prevalent feature of the hypertrophic heart.
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Pathologic remodeling that produces a prominent in-
crease in cardiac chamber volumes is called dilation.
This is a common compensatory response to diminishedOverview
contractile function that results from myocyte diseaseHeart failure is a world-wide public health problem that
or myocyte death. Ventricular dilation is almost alwaysaffects 4.5 million patients in the United States, necessi-
accompanied by modest increases in ventricular walltates one million hospitalizations each year, and causes
thickness, which reflect myocyte hypertrophy as well as300,000 deaths annually (reviewed in Cohn et al., 1997).
variable increases in interstitial fibrosis. The expansionEstimates of the annual healthcare expenditure on heart
of intraventricular volume, which reflects changes in car-failure exceed $17 billion, costs that are expected to
diac physiology, stretches cardiac myocytes and im-increase as the U.S. population ages. Heart failure is a
proves pressure–volume relationships within the heartcomplex pathophysiologic condition that arises when
so as to augment cardiac output.myocardial performance is insufficient to adequately
While compensatory cardiac remodeling processessupply blood to other organs. This syndrome is a com-
are initially beneficial to heart function, these may ulti-mon complication that ensues from a wide variety of
mately become maladaptive. Hypertrophic and dilatedcardiovascular pathologies including coronary artery
cardiac morphologies increase myocardial strain, aug-atherosclerosis, cardiomyopathy, valvular heart dis-
ment metabolic demands and, by impeding ventricularease, or congenital malformations.
relaxation, may compromise coronary artery blood flow,The failing human heart differs from normal in struc-
which predominantly occurs during the diastolic phaseture as well as in function. The normal heart is an efficient
of the cardiac cycle. Cardiac remodeling can thereforemuscle that is exquisitely designed to serve both as
accelerate functional deterioration and the onset ofpump and integrator of two independent vascular sys-
heart failure.tems, the pulmonary and systemic circulations. Two
Although the gross anatomic and histologic findingsthin-walled atria function as reservoirs for returning
in cardiac hypertrophy and dilation are well described,blood. In diastole (cardiac relaxation), blood from the
the cellular and molecular events that trigger compensa-atria enters the muscular ventricular chambers with little
tory forms of cardiac remodeling are largely unknown.impedance. During cardiac contraction (systole), the
In contrast, there has been significant progress in deline-right ventricle propels blood into the low-pressure pul-
ating causes of primary cardiomyopathies, disorders of
monary vascular beds where gaseous diffusion occurs,
heart muscle that similarly remodel the myocardium, but
while the left ventricle ejects equivalent volumes through-
do so in the absence of another underlying pathology.
out the much larger sized and greater resistance vessels Primary cardiomyopathies are traditionally classified ac-
of the systemic circulation. Commensurate with vascu- cording to anatomic and hemodynamic findings as hy-
lar load and resistance, the normal muscle mass of the pertrophic, dilated, or restrictive (in which cardiac filling
left ventricle is greater than that of the right ventricle. is impaired without changes in ventricular morphology).
In response to cardiovascular diseases, the morphol- Prior to the past decade, cardiomyopathies were be-
ogy of the heart is remodeled (Figure 1), most often along lieved to result from unrecognized nutritional, infectious,
one of two different patterns, hypertrophy or dilation. or toxic etiologies or were termed “idiopathic” and unex-
Remodeling processes can be compensatory mecha- plainable. Poor clinical outcomes, heart failure, and sud-
nisms that help to preserve pump function in disease den death events that occurred in individuals affected
states. Conditions such as hypertension or cardiac aor- with these disorders heightened the awareness of these
tic valve pathology can cause ventricular hypertrophy intriguing disorders. With the recognition that many pri-
(defined as increased muscle mass) in order to accom- mary cardiomyopathies are familial, and with delineation
modate increased load. Hypertrophy is clinically recog- of Mendelian patterns of transmission, strategies used
nized by cardiac imaging, which documents increase in to study these disorders shifted toward human molecu-
ventricular wall thickness. Myocardial hypertrophy as- lar genetic methods. This productive approach led to a
sociated cardiac remodeling occurs through increases fundamental change in conventional paradigms about
in the size of cardiac muscle cells (myocytes), not the causes of cardiomyopathies: many of these “idio-
through increases in myocyte number (hyperplasia). Hy- pathic” disorders are now known to result from heritable
pertrophy is often associated with increases in intersti- gene mutations.
tial fibrosis, where more cardiac fibroblasts and associ- Identification of mutations in patients with cardiomy-
ated extracellular matrix are present than in the healthy opathies has revealed substantial molecular complexity
heart. Interstitial fibrosis increases cardiac stiffness and in the etiologies of these disorders. Mutation of any one
of 10 different genes can cause the “single” clinical
entity of hypertrophic cardiomyopathy. While causal* E-mail: seidman@rascal.med.harvard.edu (J. G. S.); cseidman@
rascal.med.harvard.edu (C. S.). mutations for only a fraction of all cases of dilated car-
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myocytes that characterize the normal myocardium (Fig-
ure 2A) becomes distorted by hypertrophic growth of
the myocytes, which can produce enlarged and bizarrely
shaped myocytes as well as disorientation (oblique or
perpendicular alignment) of adjacent cells (Figure 2B).
These findings, collectively termed myocyte disarray,
can be focal and juxtaposed beside normal appearing
myocardium or can be widespread throughout the ven-
tricle. With premature death of hypertrophic myocytes,
the cardiac fibroblasts and associated extracellular ma-
trix increase (often referred to as “replacement” fibrosis)Figure 1. Patterns of Cardiac Remodeling
and further contribute to the distortion in myocardialThe normal myocardium can be remodeled by heritable gene muta-
tions and acquired diseases into hypertrophic or dilated morpholo- cell architecture.
gies. Note the normal left ventricular wall thickness and chamber Despite the presence of even markedly abnormal
volume of the healthy heart (B) in comparison to the robust increase ventricular morphology and histopathology, contractile
in left ventricular wall thickness of hypertrophic cardiomyopathy (A)
(systolic) function in hypertrophic cardiomyopathy isand the marked increase in left ventricular chamber volumes of
usually excellent and can often appear supra normal.dilated cardiomyopathy (C). Atrial enlargement is also evident in
Yet, most affected individuals develop mild to moderateboth cardiomyopathies.
symptoms of shortness of breath (dypsnea) and chest
pain (angina) due to impaired diastolic relaxation of the
diomyopathy have been defined, genetic mapping stud- hypertrophic heart (Spirito et al., 1997). In addition, pa-
ies indicate this disorder will similarly exhibit substantial tients are at risk for heart failure, atrial and ventricular
inter- and intragenic heterogeneity. Restrictive cardio- arrhythmias, and sudden death. In the United States,
myopathy remains an enigma; neither disease loci nor unrecognized hypertrophic cardiomyopathy is the most
mutated genes have been discovered to cause this rarer common cause for sudden death in athletes.
type of cardiomyopathy. Diagnosis of hypertrophic cardiomyopathy is made
The importance of identifying precise genetic causes by two-dimensional echocardiography, a noninvasive
for cardiomyopathies may extend beyond the molecular cardiac imaging technique that reveals the extent and
insights into these specific maladies. With the recent distribution of hypertrophy and delineates cardiac con-
development and analyses of genetically engineered tractile function. Echocardiograms from a large popula-
models of human cardiomyopathy mutations comes the tion of young individuals have estimated the incidence of
opportunity to define critical molecules and pathways hypertrophic cardiomyopathy to be 1 in 500 individuals
that participate in cardiac remodeling. Since similar pat- (Maron et al., 1995). The wide-spread use of echocardi-
terns of cardiac remodeling occur in response to more ography has not only confirmed autosomal dominant
prevalent, acquired cardiovascular diseases, mechanis- transmission of disease, it has identified age-dependent
tic insights derived from the study of genetic disorders penetrance of the disease and documented marked vari-
may be relevant to a wide range of heart conditions that ation in the extent and distribution of the hypertrophy.
remodel the heart and contribute to heart failure. Molecular genetic studies of familial hypertrophic car-
diomyopathy help to explain the clinical diversity of this
Hypertrophic Cardiomyopathy condition. Linkage analyses provided the first evidence
A primary disorder of the myocardium, hypertrophic car- for allelic heterogeneity with sequential definition of dis-
diomyopathy causes distinctive anatomic and histologic ease loci on chromosomes 14q11 (Jarcho et al., 1989),
features as well as a wide array of clinical manifestations 1q32 (Watkins et al., 1993), 15q22 (Thierfelder et al.,
(Fatkin et al., 2000a and references therein). Cardiac 1993), and 11p11 (Carrier et al., 1993). Demonstration
mass is increased due to left ventricular wall thickening that human mutations in the b cardiac myosin heavy
(hypertrophy) that most often is asymmetric, often with chain, cardiac troponin T, a tropomyosin, and cardiac
particular involvement of the interventricular septum. myosin binding protein C genes were encoded at these
As a consequence of hypertrophy, the left ventricular loci, led to the conclusion that hypertrophic cardiomyop-
chamber volumes are diminished, resulting in the ap- athy resulted from defects in cardiac sarcomere proteins
pearance of a muscle-bound heart (Figure 1A). Histopa- (for a review, see Seidman and Seidman, 2000). Muta-
thology in hypertrophic cardiomyopathy can be strik- tions in cardiac actin (Mogensen et al., 1999), troponin I
(Kimura et al., 1997), the essential and regulatory myosiningly abnormal. The highly registered alignment of
Figure 2. Histopathology of Hypertrophic and
Dilated Cardiomyopathy
(A) The normal architecture of healthy ventric-
ular myocardium shows orderly alignment of
myocytes with minimal interstitial fibrosis.
(B) Marked enlargement and disarray of myo-
cytes (red) with increased interstitial fibrosis
(blue) is evident in hypertrophic cardiomy-
opathy.
(C) The histology of dilated cardiomyopathy shows hypertrophy and degeneration of myocytes (dark red) without disarray. Increases in
interstitial fibrosis (pale pink) is evident. (Stains: [A and C], hematoxylin and eosin; [B], mason trichrome)
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Pi, force is generated (termed the power stroke), and
the initial unbound conformation of myosin is restored.
(Rayment et al., 1993). Transmission of force generated
by the sarcomere to the myocyte cytoskeleton occurs
through a complex of molecules including cardiac myo-
sin binding protein C, titin, dystrophin, and associated
sarcoglycan peptides (Schiaffino and Reggiani, 1996).
These provide elasticity to the cell and may also modu-
late contractile force.
There are several different mechanisms by which mu-
tations in genes encoding sarcomere proteins could pro-
duce hypertrophic cardiomyopathy. Some dominant
gene mutations inactivate an allele, resulting in a re-
duced amount of functional protein (haploinsufficiency),
while other dominant gene mutations create a mutant
protein that interferes with normal protein function
(dominant negative) or that has a novel function. MostFigure 3. The Sarcomere Produces Muscle Contraction by Sliding
hypertrophic cardiomyopathy mutations (Table 1 andof Myofilaments
references contained in Seidman and Seidman, 2000)Proteins in the thin filament include the troponin complex (T, C, and
are missense mutations or minor truncations that areI), actin, and a tropomyosin. Myosin heavy chain and light chains are
constituents of the thick filaments. Contraction begins with calcium unlikely to cause haploinsufficiency through either tran-
entry into the sarcomere (see Figure 5) that releases troponin I script or peptide instability. Indeed, of more than 50
inhibition of actin and enables actin–myosin binding. Myosin, the different point mutations in the b cardiac myosin heavy
molecular motor of the sarcomere, hydrolyzes ATP and undergoes
chain gene, none encode premature termination signals;a series of conformational changes, initiated in the globular head
all produce missense codons. Although hypertrophicdomain and transmitted through flexible joints to the rod domain,
cardiomyopathy mutations in other sarcomere proteinso that the thick filament is propelled with respect to the thin fila-
ment. As calcium is sequestered by the sarcoplasmic reticulum, genes, particularly cardiac troponin T and myosin bind-
troponin I inhibition of actin–myosin interactions is reestablished ing protein C, can be missense or short in-frame inser-
(adapted from Kamisago et al., 2001). tions and deletions, or can alter splice signals, analyses
indicate these transcripts encode stable mutant proteins
that are incorporated into cardiac myofilaments (Wat-light chains (Poetter et al., 1996), and titin (Satoh et al.,
kins et al., 1996; Rust et al., 1999). An important question1999) are currently also recognized as rare causes of
to emerge from such data is, then, do mutant sarcomerehypertrophic cardiomyopathy.
components produce the dramatic morphologic andThe sarcomere is a functional unit of contraction
physiologic features associated with hypertrophic car-within myocytes. The protein constituents of sarco-
diomyopathy because they impair normal protein func-
meres are organized into thick and thin filaments (Figure
tion or because they produce new functions?
3), which, in the context of repetitive series of sarco-
An approach used to address this question has been
meres, account for the microscopic appearance of myo-
to predict the consequences of hypertrophic cardiomy-
filament cross striations in muscle cells. Contraction opathy mutations based on molecular structures of sar-
occurs by sliding and interdigitating of the thick and thin comere proteins in conjunction with biochemical and
filaments of sarcomeres. Myosin heavy chain, myosin biophysical information about muscle contraction. Al-
binding protein C, and myosin essential and regulatory though there is considerable relevant information on
light chains are found in the thick filament, with which both actin and myosin, fewer than five human actin mu-
the massive protein titin associates. The thin filament tations are known to cause cardiomyopathy, so infer-
contains actin, the troponin complex (troponins I, C, and ences remain limited. In contrast, myosin mutations are
T), and tropomyosin. a prevalent cause of cardiomyopathies. Based on the
Myofilaments slide through the sequential attachment three-dimensional crystal structure of the chicken myo-
of thick filament myosin and thin filament actin, energy- sin head (Rayment et al., 1995), human hypertrophic
dependent conformational changes in myosin, and then, mutations have been located (Figure 4, blue spheres) in
actin-myosin release. The globular head of myosin myosin head domain residues that interface with actin
heavy chain, which is connected through a flexible re- or that surround the nucleotide (ATP) binding pocket.
gion to the rod domain (Figure 3 and 4) contains both Other defects occur in residues that comprise a flexible
enzymatic activity for ATP hydrolysis and sites for bind- fulcrum in myosin, or that bind myosin light chains. The
ing actin; as such, the myosin head is often considered absence of clear clustering of human hypertrophic de-
the motor in sarcomeres. Contraction is initiated when fects within any one functional domain of myosin may
cytosolic calcium rises and binds the troponin complex be interpreted to indicate that a change in any of the
(composed of subunits C, T, and I) and a tropomyosin. specific biophysical events during muscle contraction
Calcium releases troponin I inhibition of actin–myosin could produce cardiac hypertrophy. However, more re-
interactions, and promptly actin becomes tightly bound cent studies of myosin mutations that cause dilation
to the myosin head. ATP then binds myosin and alters (described below) suggest otherwise.
the conformation of the actin binding sites within myo- The construction of animal models of mutated myo-
sin, so that head domain is displaced along the thin sins identified from patients with hypertrophic cardio-
myopathy has allowed more rigorous assessment offilament. With ATP hydrolysis and release of ADP and
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Figure 4. A 3D Representation of the Actin–
Myosin Complex, with Myosin Portrayed in
the Post-Power Stroke (Rigor Conformation)
after Separation from Actin
One myosin head and two actin monomers
are displayed with actin–myosin binding do-
mains (green), ATP binding domain in myosin
(yellow), and the myosin essential (orange)
and regulatory (violet) light chains high-
lighted. The separation of actin and myosin
has been increased for clarity. Residues in
actin and myosin that are mutated in hyper-
trophic cardiomyopathy are shown in blue;
residues that are mutated in dilated cardio-
myopathy are shown in red (adapted from
Rayment et al., 1993; Schroeder et al., 1993;
and Seidman and Seidman, 2000).
specific processes that are perturbed by these defects. 1998), and troponin T (Oberst et al., 1998; Tardiff et al.,
1998) have been genetically engineered into genomesAnimal models have been particularly valuable both be-
cause stable cell lines of myocyte lineages do not exist, of mice and rabbits (Marian et al.,1999). These models
exhibit many characteristics of the human disease, in-and because traditional studies of nongenetic forms of
cardiac hypertrophy produced by surgical or pharmaco- cluding cardiac hypertrophy and histopathologic fea-
tures of myocyte disarray with increased interstitial fi-logical interventions indicate the importance of inte-
grative organ physiology in cardiac remodeling. Human brosis and altered cardiac physiology. A consistent
finding from analyses of these models indicates thatmutations in myosin heavy chain (Geisterfer-Lowrance
et al., 1996), myosin binding protein C (Yang et al., cardiac phenotype is not the consequence of haploin-
Table 1. Genetic and Clinical Heterogeneity of Human Cardiomyopathy
Locus Additional Phenotype Disease Gene Mutation Type
Hypertrophic
1q32 None Cardiac Troponin T Missense, Deletions, Splice Defects
2q31 None Titin Missense
11p11 None Cardiac Myosin Binding Protein-C Missense, Deletions, Splice Defects
14q12 None Cardiac b Myosin Heavy Chain Missense
15q14 None Cardiac Actin Missense
15q22 None a Tropomyosin Missense
19q13 None Cardiac Troponin I Missense
3p21 Skeletal Myopathy Essential Myosin Light Chain Missense
12q23-p21 Skeletal Myopathy Regulatory Myosin Light Chain Missense
7q3 Pre-excitation ?
Dilated
1q32 None Cardiac Troponin T Deletions
1q32 None ?
2q11-q22 None ?
2q31 None ?
9q13-q22 None ?
14q11 None Cardiac b Myosin Heavy Chain Missense
15q14 None Cardiac Actin Missense
10q21-q23 Mitral Valve Prolapse ?
1p1-q21 Conduction Disease Lamin A/C Missense
2q11-q22 Conduction Disease ?
3q22-p25 Conduction Disease ?
19q13.2 Conduction Disease ?
2q35 Skeletal Myopathy Desmin Missense
6q23 Skeletal Myopathy ?
Xp21 Skeletal Myopathy Dystrophin Deletions
Xq28 Short Stature & Neutropenia Tafazzin Deletions, Splicing Defects
6q23-24 Sensorineural Hearing Loss ?
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sufficiency or altered stoichiometry of sarcomere com- cardiac hypertrophy indicate that angiotensin II medi-
ates growth of cultured myocytes by causing significantponents, but rather occurs from the dominant effects
of mutant proteins on sarcomere function. In addition, changes in Ca21 concentration (Ito et al., 1997). In-
creases in Ca21 concentrations have also been observedthe levels of mutant sarcomere protein expressed within
the heart correlates with myocyte dysfunction (Yang et in myocytes taken from rats with surgically produced
pressure-overload-induced hypertrophy (Zolk et al., 1998).al., 1998), although not directly with the development of
hypertrophy. For example, mice that are homozygous Recent studies of the calcium-dependent phosphatase
calcineurin A (Molkentin et al., 1998) could provide afor a myosin missense mutation (Fatkin et al., 1999a)
have profoundly reduced contractile function and die molecular pathway by which calcium could activate
cardiac hypertrophy: overexpression of a calcineurinshortly after birth in severe heart failure but exhibit little
cardiac hypertrophy. transgene expressed in the heart of mice caused dephos-
phorylation and nuclear translocation of the transcriptionStudies of one human hypertrophic cardiomyopathy
myosin missense mutation, Arg403Gln, has been partic- factor NF-AT3. The cardiac hypertrophy observed in this
transgenic model could be abrogated by administrationularly fruitful in addressing the question of whether these
defects cause a loss or gain in function. Residue 403 is of the calcineurin inhibitor, cyclosporin A (Molkentin et al.,
1998). Transcriptional activation of hypertrophic genes bylocated at the base of an actin binding loop in the myosin
heavy chain (Rayment et al., 1995); substitution at this NF-AT3 in association with other molecules such as
GATA4, might then result in myocyte growth.position could alter loop structure and actin interactions.
Analyses of isolated fibers (Cuda et al., 1997) from the Additional evidence for a role of calcium pathways in
regulating growth of myocytes comes from studies ofsoleus (leg) muscle of humans with this heterozygous
myosin defect demonstrated decreased mechanical myosin mutants. Normal myocytes respond to cal-
cineurin inhibition (achieved by cyclosporin A adminis-function. While this finding was consistent with a domi-
nant-negative effect, these studies were limited to analy- tration) by increasing resting intracellular calcium concen-
tration (Fatkin et al., 2000b). In contrast, myocytes thatses of skeletal muscle that express very low levels of
cardiac myosin isoforms. More recent analyses of car- express the myosin mutation Arg403Gln fail to elevate
intracellular free calcium in response to these agents. Sur-diac muscle have suggested a different conclusion.
Characterization of myosin that contains only the prisingly, the development of hypertrophic cardiomyopa-
thy in mice engineered to contain the myosin Arg403GlnArg403Gln missense mutation (Tyska et al., 2000) iso-
lated from hearts of mice engineered to carry this defect mutation is markedly accelerated and severe in response
to cyclosporin treatment (Fatkin et al., 2000b). The en-exhibited enhanced actin-activated myosin ATPase ac-
tivity, increased generated force, and accelerated actin hanced hypertrophy and worsened histopathology in-
duced by this agent could be blocked by coadministrationfilament sliding, all consistent with a gain in myosin
functions. An appealing aspect of these findings is that of calcium-channel inhibitors. While the precise signaling
pathways that account for these observations remain un-they suggest a molecular mechanism for the supra nor-
mal cardiac performance that is often evident in humans known, these data imply that myosin mutations cause
a fundamental dysregulation of calcium.with hypertrophic cardiomyopathy. It is noteworthy that
the consequences of a gain in myosin function would Ca21 concentrations are stringently controlled in myo-
cytes (reviewed in Mackrill, 1999), because of the inti-not be entirely beneficial. Although there was an im-
provement in motor performance of individual myosin mate role that this ion plays in myofilament contraction.
Variation in calcium concentrations during relaxationArg403Gln molecules, heterogeneity of mutant and wild-
type myosin proteins within the sarcomere would likely and contraction is precisely orchestrated through sub-
cellular compartmentalization of this ion in the sar-uncouple the mechanical coordination that normally
occurs between myosin heads. In addition, enhanced coplasmic reticulum and sarcomere (Figure 5). Ca21
crosses the myocyte plasma membrane through L-typeATPase activity would result in higher levels of energy
consumption by the hypertrophic heart. If energy con- (dihydropyridine) Ca21 channels, which are in close
proximity to intracellular ryanodine receptors that spansumption exceeded energy supply, hypertrophic myo-
cytes might die prematurely. And since myocytes can the sarcoplasmic reticulum. Calcium induces activation
of ryanodine receptors, resulting in rapid release of se-not replicate, proliferation of cardiac fibroblast would
ensue and cause replacement fibrosis, a well-recog- questered calcium from the sarcoplasmic reticulum to
the cytoplasm, which triggers sarcomere contraction.nized histopathologic feature of this disease. While at
present it is unknown whether a gain in function is unique Calcium is removed from the sarcomere and cytoplasm
after contraction through the activity of a calcium-to the Arg403Gln mutation in myosin, or occurs with
other defects, these unexpected data indicate the im- ATPase pump (SERCA), which restores Ca21 to the sar-
coplasmic reticulum. In addition, the sarcoplasmic retic-portance of biophysical information for an appropriate
understanding of the mechanism by which hypertrophic ulum contains muscle-specific Ca21 binding proteins,
including calsequestrin and calpactin, which serve tocardiomyopathy mutations cause disease.
An important corollary to the conclusion that sarco- buffer free calcium.
One mechanism by which the Arg403Gln mutationmere mutations alter the molecular processes of muscle
contraction is that these events also activate pathways could produce dysregulation of subcellular calcium con-
centrations might be through altered sarcomere Ca21for myocyte growth. Although little is currently known
about signaling pathways that link sarcomere force pro- requirements. If by perturbing the biophysical events of
contraction, this mutation chronically increased calciumduction to myocyte growth, and ultimately cardiac hy-
pertrophy, evidence implicates a critical role for calcium contained in the sarcomere, a relative depletion of this
ion might occur within the sarcoplasmic reticulum. Cal-in signal transduction. Studies of nongenetic causes of
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Figure 5. A Schematic of the Myocyte Struc-
tures that Contain Mutations (*) that Remodel
the Human Heart
Human mutations in sarcomere protein are
currently the only known genetic causes of
hypertrophic remodeling. Mutations in pro-
teins of the thin and thick filament of the sar-
comere, cytoskeletal sarcoglycans, interme-
diate filament proteins, and nuclear envelope
proteins can cause cardiac dilation. Genetic
studies in man and model organisms indicate
calcium dysregulation occurs in response to
gene mutations that trigger cardiac remodel-
ing. Calcium enters the myocyte through
L-type (dihydropyridine) Ca21 receptors to
activate ryanodine receptors (RyR), thereby
triggering calcium-induced calcium release
(CICR). Increased calcium activates sarco-
mere contraction (see Figure 3). Activation of
calcium ATPase pump (SERCA), which is reg-
ulated by phospholamban (PLN) removes cal-
cium from the cytoplasm and restores sarcoplasmic reticulum levels. The sarcoplasmic reticulum contains calcium binding proteins that may
be essential components for activating genetic programs of cardiac hypertrophy and dilation. (Adapted from Fatkin et al., 2000b).
cium imbalance might then activate signals for hypertro- have in this disease permits accurate gene-based diag-
nosis and the potential to identify individuals at riskphic growth. Given the critical role of Ca21 in actin and
myosin interactions and evidence that dysregulation of for the most serious consequences of the disease. For
researchers, the ongoing molecular dissection of theCa21 release and/or sequestration occurs in a wide
range of cardiac disease, proteins that regulate myocyte pathways triggered by sarcomere dysfunction contin-
ues to yield mechanistic insights into myocyte growth,handling of Ca21 appear to be promising candidates for
signaling molecules that remodel the heart (Figure 5). a process that may be fundamentally linked to myocyte
disarray and myocyte death. Continued progress in elu-Elucidation of the full repertoire and functions of Ca21
interacting molecules should therefore aid the discovery cidating these pathways has raised the expectation that
beneficial treatments for hypertrophic cardiomyopathyof mechanisms by which aberrant sarcomere contrac-
tion signals hypertrophic growth. will someday be a reality.
Both the diversity of mutations and the number of
genes that can be mutated to cause hypertrophic car- Dilated Cardiomyopathy
Defined by ventricular dilation and diminished contrac-diomyopathy have been interpreted to indicate this dis-
order occurred recently in human evolution. Genetic tile function, dilated cardiomyopathy is a prevalent
world-wide disorder that is estimated to affect 36.5 peranalyses of cases of sporadic hypertrophic cardiomyop-
athy (affected individuals with unaffected parents) have 100,000 individuals (Cohn et al., 1997). Dilated cardiomy-
opathy causes heart failure, serious arrhythmias (irregu-affirmed this model (Watkins et al., 1992; Greve et al.,
1994) by documenting de novo mutations that cause lar heart rhythm), and thromboembolic (blood-clot-
related) events, all of which account for the substantialthis disease. Although some founding mutations have
been identified in a few populations (Jaaskelainen et al., morbidity and premature mortality of this disease. The
pathologic manifestations of dilated cardiomyopathy1998), haplotype analyses indicate that even hypertro-
phic cardiomyopathy defects that are shared by unre- are often nonspecific. Although cardiac mass is in-
creased, there is often only modest ventricular wall hy-lated individuals reflect independent genetic events.
The substantial molecular heterogeneity in hypertro- pertrophy while atrial and ventricular chambers (Figure
1C) can be mildly or markedly distended. Microscopicphic cardiomyopathy also appears to account for some
of the variable clinical manifestations observed in af- examination may reveal no abnormalities or evidence
of abnormal histopathology in the myocardium such asfected individuals. The age of onset of hypertrophy, the
extent and pattern of cardiac remodeling, and an af- myocyte hypertrophy, myocyte degeneration, and in-
creased interstitial fibrosis (Figure 2C). Unlike hypertro-fected individual’s risk of death from the disease (heart
failure and/or sudden death) are influenced by the pre- phic cardiomyopathy, substantial distortions of cell ar-
chitecture or myocyte disarray are not features of dilatedcise genetic cause (reviewed in Fatkin et al., 2000a).
With continued delineation of the clinical profiles that cardiomyopathy.
Clinical manifestations of disease (reviewed in Bozkurtare associated with particular mutations, genotype infor-
mation is expected to contribute to patient management and Mann, 2000) in the early stages of dilated cardio-
myopathy are vague and often not attributed to heartin hypertrophic cardiomyopathy (Spirito et al., 1997).
The progress in molecular genetic research of hyper- disease. Affected individuals develop symptoms of easy
fatigue, exertional dyspnea (shortness of breath), or pal-trophic cardiomyopathy has provided insights that are
relevant to both clinical cardiology and cardiac muscle pitations. Further deterioration in contractile function
and progression toward heart failure or onset of atrial andbiology. For physician and affected individuals, defini-
tion of the causal role that sarcomere gene mutations ventricular arrhythmias worsens symptoms. Diagnosis of
Review
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dilated cardiomyopathy is based on the finding of in- (Chen and Chien, 1997; Towbin et al., 1999), more recent
studies demonstrate that deficits in force production bycreased cardiac systolic and diastolic dimensions with
diminished contractile function. When underlying causes the sarcomere also cause this disease. Still other human
gene mutations indicate that an insidious deteriorationsuch as coronary artery disease, chronic alcohol abuse,
thyroid disease, or viral infection are excluded as etiolo- in myocyte viability may account for the development
of ventricular remodeling and dysfunction.gies, a diagnosis is often made of idiopathic dilated cardio-
myopathy. Over the past decade, family studies (Grunig In all striated muscles, contractile force is transmitted
from the sarcomere to the extracellular matrix throughet al., 1998) and echocardiographic evaluations of relatives
of affected individuals have demonstrated that approxi- an oligomeric complex containing dystrophin and sarco-
glycans located beneath the myocyte plasma membranemately 25%–30% of “idiopathic” dilated cardiomyopathy
is caused by an inherited gene mutation. (Figure 5). This complex is dysfunctional in heritable
muscular dystrophies, a group of progressive skeletalFamilial dilated cardiomyopathy can be transmitted
as an autosomal recessive, X-linked, or matrilinear (mi- muscle disorders that arise from mutations in the genes
encoding dystrophin and other sarcoglycans (Straubtochondrial) trait, but autosomal dominant inheritance
occurs most often. While this pattern of transmission and Campbell, 1997). Cardiac dysfunction is a well rec-
ognized comorbidity that occurs during the natural his-fosters application of molecular genetics to identify dis-
ease-causing mutations, progress in this field was ini- tory of several limb-girdle muscular dystrophies. But
intriguingly, some mutations in the dystrophin–sarco-tially quite slow. Disease onset after middle age and
incomplete penetrance (absence of phenotype in genet- glycan complex cause preeminent cardiac disease: ven-
tricular dilation and dysfunction with subclinical or mini-ically affected individuals) hindered accurate diagnosis
of family members. These factors in addition to the sub- mal skeletal muscle dystrophy. Human mutations in
sequences of the dystrophin gene promoter (Ortiz-Lopezstantial premature mortality associated with this disease
limited the number of families that were of sufficient size et al., 1997) and a naturally occurring deletion in the d
sarcoglycan gene of hamsters (Nigro et al., 1997) eachfor genome-wide linkage strategies, and hence, initial
genetic analyses were often restricted to assessment appear to selectively perturb cardiac muscle. Recent
studies indicate that disturbances in the dystrophin–of the role of candidate molecules in dilated cardiomy-
opathy. However, with the expanded repertoire of highly glycoprotein complex may also underpin dilated cardio-
myopathy that sometimes evolves following myocardi-informative polymorphic markers that have become
available throughout the past five years, pedigree size tis, an acute inflammatory cardiac disease caused by
adenovirus or enterovirus infection. Enteroviral proteasehas been less problematic and genetic linkage analyses
of human dilated cardiomyopathy have been increas- 2A has been shown to specifically cleave dystrophin
(Badorff et al., 1999), raising the hypothesis that viral-ingly productive. Although the number of human muta-
tions identified in disease genes still remains limited mediated proteolysis might occur during myocarditis,
to produce functional deficits equivalent to dystrophin(Table 1), to date more than 15 loci for dilated cardiomy-
opathy are known and more can be expected. mutations. These data suggest a potential mechanism
that is common to the pathophysiology of acquired andIn addition to demonstrating substantial heterogene-
ity of heritable dilated cardiomyopathy, these investiga- heritable cardiomyopathies.
The presumed mechanism by which heritable muta-tions have demonstrated that a wide spectrum of clinical
phenotypes can accompany this disorder (Grunig et al., tions or acquired deficiencies of the dystrophin–sarco-
glycan proteins diminish cardiac contraction is thought1998; Mestroni et al., 1999). These include cardiac fea-
tures as well as noncardiac manifestations (Table 1). to be through ineffectual propagation of force from the
sarcomere to the extracellular matrix. Deficits in forceSeveral genetic loci have been defined that cause elec-
trical physiologic abnormalities (atrial–ventricular con- transmission would presumably signal compensatory
responses in the myocyte and heart that result in cardiacduction delay) that arise not as a consequence of ven-
tricular dilation and dysfunction, but in advance of remodeling (myocyte hypertrophy and ventricular dila-
tion) in an attempt to augment systolic function. An alter-cardiac remodeling. Muscular dystrophy is another
prevalent associated phenotype (Mestroni et al., 1999), native mechanism has been suggested from comparison
of mice engineered to lack either the muscle-specific awhich may result when defects perturb cellular pro-
cesses that are common to all striated muscle. In other subunit or the more broadly expressed d subunit of this
sarcoglycan complex (Cora-Vazquez et al., 1999). Whileinstances, an associated clinical manifestation is seem-
ingly unexplainable, such as a form of sensorineural each mutation produces muscular dystrophy in mice,
only the a sarcoglycan–deficient mice developed dilatedhearing loss that precedes by several decades the onset
of dilated cardiomyopathy (Schonberger et al., 2000). cardiomyopathy. Surprisingly, the inciting event for
heart disease was not an intrinsic defect in myocyteDiscovery of the molecular basis for these usual pheno-
types may therefore provide opportunity to learn about structure or function but rather malformations within the
coronary artery tree. Loss of the a sarcoglycan alteredpreviously unrecognized aspects of myocyte biology.
Identification of genetic causes for dilated cardiomy- the cytoskeletal integrity of vascular smooth muscle suf-
ficiently to perturb vascular architecture and diminishopathy has indicated several potential mechanisms by
which heart muscle can fail. Effective muscle contrac- coronary artery blood flow. While these findings are un-
likely to be directly relevant to most forms of dilatedtion requires force generation by the sarcomere and
force transmission to the cytoskeleton and the extracel- cardiomyopathy, recognition of an ischemic component
in even a subset of dystrophin–sarcoglycan muscle dis-lular matrix. Although early discoveries suggested that
ineffectual force transmission was the essential deficit ease in humans will have important therapeutic implica-
tions.in myocyte function that caused dilated cardiomyopathy
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A better understanding of the role that structural pro- tions that cause hypertrophic cardiomyopathy (Figure 4,
blue spheres), the location of these defects (red spheres)teins play in myocyte biology has sparked consideration
of additional molecules as candidates for mutations that predicts that force production by the contractile appara-
tus may be diminished.cause cardiac and skeletal muscle disease. Multiple
muscle-specific proteins of unknown function reside Deficits in sarcomere force production may also be
the consequence of the cardiac troponin T mutationwithin the cytoplasm. Targeted disruption of murine
genes that encode the actin-associated cytoskeletal that causes dilated cardiomyopathy. In two unrelated
families, a deletion of one of five highly conserved lysinemuscle LIM protein (Arber et al., 1997) or the intermedi-
ate filament protein desmin that connects sarcomere to codons (DLys210) was identified. This deletion is likely
to weaken complementary ionic interactions with a ringplasma membrane (Milner et al., 1996), disrupted normal
myocyte architecture and caused myocyte degenera- of acidic residues located on the surface of cardiac
troponin C (Filatov et al., 1999), the binding partner oftion and death. In the hearts of mutant mice, these
events caused dilated cardiomyopathy. Such findings troponin T. Because the troponin complex regulates cal-
cium-stimulated actin–myosin ATPase activity, defectsprompted analyses of desmin as a candidate cause of
human myopathies that affect both skeletal and heart in troponin T could diminish energy production for actin–
myosin detachment and reattachment, and thereby re-muscles, and subsequently, desmin mutations have
been reported (Goldfarb et al., 1998; Li et al., 1999). duce contractile force within the sarcomere.
The demonstration that allelic mutations in cardiacDeficits in this protein may render myocytes more sus-
ceptible to mechanical stresses associated with con- actin, b cardiac myosin heavy chain, and cardiac tropo-
nin T produce either hypertrophic or dilated cardio-traction. Weakened myocytes and/or premature death
of these cells could presumably reduce contractile func- myopathy might be interpreted to indicate that other
genetic factors influence development of either the hy-tion and trigger pathways for cardiac remodeling.
A candidate gene strategy also revealed that cardiac pertrophic or dilated pathology. In hamsters, a single
mutation produces either hypertrophic or dilated cardio-actin mutations are a rare cause of autosomal dominant
dilated cardiomyopathy that occurs without any other myopathy in two related strains, presumably due to the
influence of modifying factors that are different in theseassociated clinical phenotypes (Olson et al., 1998). Actin
has dual functions within the myocyte. As a critical com- genetic backgrounds (Cora-Vazquez et al., 1999). How-
ever, humans exhibit marked concordance between ge-ponent of the sarcomere, this molecule interacts directly
with myosin to produce force. Actin is also linked to notype and cardiac morphology. Even affected family
members who are quite distantly related but share another cytoskeletal proteins, and functions to propagate
contractile force throughout the myocyte. The location identical gene mutation exhibit the same morphologic
pattern of cardiomyopathy. Further, although more thanof two missense mutations demonstrated to cause hu-
man dilated cardiomyopathy on the three-dimensional 50 independent missense mutations in myosin have
been shown to cause hypertrophic cardiomyopathy,crystal structure of actin (Figure 4) predict deficits in
actin–cytoskeletal interactions, not actin–myosin inter- none of these alter residues 532 or 764, amino acids
that are mutated in dilated cardiomyopathy. And of theactions. These data have been interpreted to indicate
that actin mutations cause defects in force transmission many defects in cardiac troponin T that cause hypertro-
phic cardiomyopathy, none affect residue 210, or theand thereby cause dilated cardiomyopathy.
In contrast to cardiac actin mutations, recent discov- flanking lysine residues that may also participate in ionic
interactions with troponin C that are affected in dilatederies of mutations in other genes suggest that deficits
in force production also result in ventricular dysfunction cardiomyopathy. Collectively, these data indicate that
the hypertrophic or dilated pattern of cardiac remodel-and dilation. Mutations have been identified in b cardiac
myosin heavy chain and cardiac troponin T (Kamisago ing is a direct consequence of a specific mutation.
The finding that both hypertrophic and dilated cardio-et al., 2001) that cause early onset heritable dilated car-
diomyopathy. As observed in patients with cardiac actin myopathy can be caused by sarcomere protein muta-
tions also raises the question of whether there are twomutations, patients with dilated cardiomyopathy due to
b cardiac myosin heavy chain or cardiac troponin T distinct programs that remodel the heart, or whether
these different morphologies reflect gradations of a sin-defects had neither additional cardiac nor extracardiac
findings. These data also imply that the other constituent gle pathway. A single pathway model might predict that
the extent of remodeling mirrors the severity of sarco-proteins of the sarcomere (Figure 3 and Schiaffino and
Reggiani, 1996) are excellent candidates for mutations mere dysfunction: mild deficits could result in hypertro-
phy, while more severe dysfunction that remained un-that cause isolated dilated cardiomyopathy.
Atomic structures and biochemical information have compensated despite hypertrophic growth might trigger
myocyte death and eventually result in cardiac dilation.been useful for inferring the functional consequences
of dilated cardiomyopathy mutations in myosin heavy Studies of genetically engineered mice support the model
for a single progressive program; mice heterozygous forchain and troponin T. A missense mutation (Ser532Pro)
in b cardiac myosin perturbs a highly conserved a helical sarcomere mutations develop hypertrophic cardiomy-
opathy (Geisterfer-Lowrance et al., 1996), whereas ho-structure located in the lower 50 kDa domain, that forms
the actin binding domain (Rayment et al., 1995). Another mozygous mice (produced by crossing heterozygotes)
develop dilated cardiomyopathy (Fatkin et al., 1999a;missense mutation, Phe764Leu is centrally located
within the flexible fulcrum of myosin (Dominguez et al., McConnell et al., 1999). However, clinical studies in hu-
mans are not consistently supportive of either the single1998), which transmits movement and directionality
from the head of myosin to the thick filament (Whittaker or the dual pathway model. The presence of myocyte
hypertrophy in dilated cardiomyopathy and the deterio-et al., 1995). Unlike b cardiac myosin heavy chain muta-
Review
565
ration of some cases of hypertrophic cardiomyopathy mechanisms by which lamin mutations cause human
into a phase that resembles dilated cardiomyopathy disease will undoubtedly provide insights into the biol-
(with diminished contractile function and expanded ogy of the nucleus and may uncover important functions
heart volumes), could be interpreted to indicate a single for these molecules in the nonmitotic cells.
program accounts for these different morphologies. In This survey should convey that there is a considerable
contrast, the phenotype of rare individuals who are ho- degree of genetic and mechanistic diversity in dilated
mozygous for a hypertrophic cardiomyopathy mutation cardiomyopathy. Deficits in myocyte force generation or
in either the b cardiac myosin heavy chain gene (Nishi force transmission, myocyte viability, and perhaps un-
et al., 1994) or in the cardiac troponin T gene (Ho et al., known nuclear processes may each trigger dilated remod-
2000) is severe cardiac hypertrophy. The absence of eling pathways that ultimately cause the heart to fail. De-
ventricular dilation in these human hearts with twice the spite the multiplicity of inciting mechanisms, the rather
dose of mutant sarcomere proteins is consistent with singular cardiac response to these diverse events may
distinct programs that remodel the heart into either hy- indicate that a few molecules are critical for monitoring
pertrophic or dilated morphologies. myocyte malfunction. Given the exquisite regulation of
In addition to deficits of force production and force calcium in various compartments throughout the cardiac
transmission, human genetic studies have uncovered cycle, and increasing evidence that calcium dysregulation
unexpected causes for dilated cardiomyopathy, particu- occurs in hypertrophic cardiomyopathy, this ion may also
larly those that occur in association with conduction be a critical factor in remodeling the heart into a dilated
system disease. Several large kindreds described with morphology (Figure 5). Studies of genetically engineered
this disorder exhibit progressive prolongation of the nor- mouse models for dilated cardiomyopathy support this
mal delay in electrical activation of the atrial and ventric- hypothesis. The absence of the actin-associated cytoskel-
ular chambers; after many years of conduction system etal muscle LIM protein results in heart failure in mice
disease, the myocardium dilates and heart failure en- (Arber et al., 1997); however, breeding LIM-deficient mice
sues. Mutations in the gene encoding lamin isoforms A with mice lacking phospholamban can abrogate cardiac
and C are one cause of this type of dilated cardiomyopa- pathology (Minamisawa et al., 1999). Phospholamban, an
thy (Fatkin et al., 1999b), but so far the site of mutations inhibitor of the SERCA pump, reduces calcium stimulated
gives little insight into the mechanisms by which disease force production; ablation of phospholamban allows com-
occurs. Lamin proteins are intermediate filaments asso- pensation for deficits in force transmission in LIM-deficient
ciated with the nucleoplasmic surface of the inner nu- hearts, presumably by increased force production. Be-
clear membrane (Figure 5; Stuurman et al., 1998). Lamins cause calcium dysregulation appears to trigger both
A and C are expressed in almost all cells, including cardiac cardiac hypertrophy and cardiac dilation, perhaps dis-
myocytes, and are thought to contribute structural integrity cordant signals from the same sensors remodel the
to the nuclear envelope and provide mechanical support heart along one or the other pattern.
for the nucleus. Lamins A and C become cytoplasmic
proteins when the nucleus disassembles during mitosis Conclusions and Perspectives
(Gerace and Blobel, 1980); lamins may participate in
It is almost inevitable that other human mutations that
reassembly of the nuclear membrane after cell division.
can cause cardiomyopathy will be discovered in the near
However, the function of lamins in nondividing cells such
future. Indeed, many genetic loci are known to cause di-
as cardiac myocytes is largely unknown.
lated cardiomyopathy, but relatively few disease genesA further puzzling aspect to the biology of lamins
have been identified. Thus, our current understanding ofis the phenotype associated with different mutations.
the molecular basis for these disorders is really quite lim-Missense codons that cause cardiomyopathy and con-
ited. Additional new discoveries of human gene mutationsduction disease but not skeletal muscle disease show
that remodel the heart can be expected to define othersome clustering in the proximal helical rod domains of
inciting events that may perturb unrecognized cellular pro-the A and C isoforms. However, null and missense
cesses to trigger programs that restructure heart mor-mutations identified in the central helical rod domain
phology and cause cardiac failure. An immediate clinicalcause juvenile-onset skeletal muscular dystrophies (au-
benefit from the discovery of human gene mutations istosomal dominant Emery-Dreifuss muscular dystrophy,
early and accurate diagnosis. While this is sometimesBonne et al., 1999; limb girdle muscular dystrophy,
viewed to be of limited value, the true worth is perhapsMuchir et al., 2000). Still other mutations in the carboxyl
best considered in light of epidemiologic data that indi-terminus of lamins A and C cause another disorder,
cates the substantial hereditary component to both car-familial partial lipodystrophy (Dunnigan type; Shack-
diomyopathy and heart failure. Improved recognitionleton et al., 2000), which is characterized by adipocyte
and intervention in advance of heart failure has consider-degeneration and insulin-resistant diabetes. The rela-
able merit for reducing the serious morbidity and mortal-tively distinct location of these disease-specific muta-
ity associated with these disorders.tions may imply that particular domains of lamin are
Continued development and study of genetically engi-critical for protein–protein interactions that might con-
neered models of cardiomyopathies enables study ofvey tissue-specificity to lamin functions. Alternatively,
the integrative physiology of multiple organ systems thatlamin mutations might simply impair the structural integ-
appear to participate in remodeling processes of therity of the nucleus, and cause premature cell death.
heart and may ultimately lead to a clearer definition ofSince the mechanical stresses that are imposed on the
molecular pathways affected by gene mutations. Eluci-nucleus in contracting cells are likely to be greater than
dation of these pathways leading from mutant proteinthose in stationary cells, myocytes might be particularly
vulnerable to lamin mutations. Further elucidation of the to disease will lead to better understanding of myocyte
Cell
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M., Atherton, J., Vidaillet, H.J., Spudich, S., Girolamin, U.D., et al.biology, and will thus aid in the discovery of new avenues
(1999b). Missense mutations in the rod domain of the lamin A/Cfor intervention. While it remains an open question
gene as causes of dilated cardiomyopathy and conduction-systemwhether interrupting processes that remodel the heart
disease. N. Engl. J. Med. 34, 1715–1724.
will improve or worsen function, nonhuman models of
Fatkin, D., Seidman, J.G., and Seidman, C.E. (2000a). Hypertrophic
cardiomyopathies provide the means to address these cardiomyopathy. In Cardiovascular Medicine, J.T. Willerson and J.N.
issues. Continued investment in the full spectrum of Cohn, eds. (Churchill Livingstone), pp. 1055–1074.
genetic research, from identification of human mutation, Fatkin, D., McConnell, B.K., Mudd, J.O., Semsarian, C., Moskowitz,
to analyses of mechanism, and development of models I., Schoen, F.J., Giewat, M., Seidman, C.E., and Seidman, J.G.
to elucidate signaling molecules, has great promise for (2000b). An abnormal Ca21 response in mutant sarcomere protein-
mediated familial hypertrophic cardiomyopathy. J. Clin. Invest. 106,advancing the science and treatment of cardiomyopa-
1351–1359.thies.
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